Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

Archives of General Psychiatry

Volumn 60, Issue 7, 2003, Pages 681-690

  Potkin, Steven G ^a   Saha, Anutosh R ^b   Kujawa, Mary J ^c   Carson, William H ^b   Ali, Mirza ^b   Stock, Elyse ^c   Stringfellow, Joseph ^c   Ingenito, Gary ^b   Marder, Stephen R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PLACEBO; PROLACTIN; RISPERIDONE;

ADULT; AGITATED DEPRESSION; ARTICLE; BODY WEIGHT; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HERNIA; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MUSCLE HYPERTONIA; NAUSEA; NEGATIVE SYNDROME; POSITIVE SYNDROME; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCALE UP; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEPARATION TECHNIQUE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; VOMITING; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; PIPERAZINES; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0038488945     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.7.681     Document Type: Article

References (36)

1. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(2 suppl):106S-115S.
2. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther. 2000;295:853-861.
3. Roth BL, Sheffler D, Potkin SG: Atypical antipsychotic drug action: unitary or multiple mechanisms for "atypicality." Clin Neurosci. In press.
4. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161-166.
5. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158:360-369.
6. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3:123-134.
7. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994;382:11-15.
8. Kurzthaler I, Fleishhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62(suppl 7):32-37.
9. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19-76.
10. Stahl SM. Essential Psychopharmacology. New York, NY: Cambridge University Press; 1996.
11. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(suppl 10):5-14.
12. Naber D, Gaussares C, Moeglen JM, Tremmel L, Bailey PE, and the SDZ HDC 912 Collaborative Study Group. Efficacy and tolerability of SDZ HDC 912, a partial dopamine D-2 agonist, in the treatment of schizophrenia. In: Meltzer HY, ed. New Research Directions in the Development of Atypical and Other Novel Antipsychotic Medications. New York, NY: Raven Press; 1991.
13. Olbrich R, Schanz H. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry. 1988;21:389-390.
14. Olbrich R, Schanz H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect. 1991;84:233-236.
15. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry. 1998;43:2-11.
16. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm. 2002;109:411-420.
17. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
18. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-[4-[(2,3-dichlorophenyl)-1-piperazinyl]butyoxy]-3,4-dihydro-2 (1H)-quinolinone (ORC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996;277:137-143.
19. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 7-{4-[(2,3-gichlorophenyl)-1-piperazinyl]butyoxy}3,4-dihydro-2 (1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic and postsynaptic D2 receptor antagonist activity. J Pharmacol Exp Ther. 1995;274:329-336.
20. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137-140.
21. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: a dopamine-serotonin system stabilizer [abstract]. Int J Neuropsychopharmacol. 2002;5(suppl 1):S176.
22. Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl). 1993;112(1 suppl):S40-S54.
23. Rao ML, Möller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment: a review. Neuropsychobiology. 1994;30:160-172.
24. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
25. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124:159-167.
26. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
27. Beasley CM Jr, Hamilton SH, Crawford AM, Deliva MA, Tollefson GD, Tran PV, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind trial. Eur Neoropsychopharmacol. 1997;7:125-137.
28. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233-246.
29. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Ouetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo: Seroquel Study Group. Arch Gen Psychiatry. 1997;54:549-557.
30. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia: US Seroquel Study Group. J Clin Psychopharmacol. 1996;16:158-169.
31. Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar GC. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract]. Int J Neuropsychopharmacol. 2000;3(suppl 1):S157.
32. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripripazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-126.
33. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86.
34. Gury C, Canceir O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale. 2000;26(6):62-72.
35. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22-31.
36. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.